RDY, US2561352038

Dr. Reddy's reports $32,350 IRS penalty: what it means for Dr. Reddy's Laboratories stock

Published on 10/06/2026 at 04:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A $32,350.20 IRS penalty was judged immaterial. Dr. Reddy's Laboratories stock had a prior close of EUR 11.00 on October 2, 2026.

RDY, US2561352038, Illustration mit AI erstellt.

Dr. Reddy's Laboratories (US2561352038) reported a $32,350.20 IRS penalty on October 2, 2026, and the company assessed the charge as immaterial to its finances and operations, according to StockTitan. At Lang & Schwarz, the prior close was EUR 11.00 on October 2, 2026.

Penalty stays financially immaterial

The penalty concerned a step-down wholly owned subsidiary that misclassified the fiscal-year reference when making a tax payment. The IRS transcript was dated September 25, 2026, and the company said the amount had no material impact on financial, operational or other activities.

The filing is a limited financial item rather than a change to Dr. Reddy's Laboratories' operating outlook. Its size is also small relative to the company's recent quarterly revenue and cash position.

June quarter exposed two pressures

In the first quarter of fiscal 2027, revenue fell 5.60 percent year over year to USD 853.00 million, while profit after tax attributable to equity holders reached USD 47.00 million, according to Benzinga. The company linked the decline to lower lenalidomide sales and semaglutide API-related costs.

The same quarter produced an EBITDA margin of 12.50 percent. Management said the margin excluding semaglutide-related effects was 15.40 percent and described the underlying base business as delivering double-digit growth across key geographies.

October results set the next test

Dr. Reddy's Laboratories' board is scheduled to consider unaudited standalone and consolidated results for the quarter ending September 30, 2026, on October 23, 2026, according to StockTitan. That report will show whether the company has begun to offset the 5.60 percent first-quarter revenue decline.

On the primary exchange, Dr. Reddy's Laboratories trades on the NYSE under RDY, and the company is identified with ISIN US2561352038 by Investing.com. The USD 10.30 billion market capitalization and USD 11.36 to USD 15.67 52-week range were quoted as of October 5, 2026.

Stock reference remains EUR 11.00

At Lang & Schwarz, Dr. Reddy's Laboratories stock had a prior close of EUR 11.00 on October 2, 2026. The next company-specific market date is October 23, 2026, when the board is scheduled to review the September quarter.